Want to see AU:BGT full AI Analyst Report?
BGT Stock Chart & Stats
AU$0.02
<AU$0.01(2.86%)
At close: 4:00 PM EDT
AU$0.02
<AU$0.01(2.86%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.06
Previous CloseN/A
Volume129.91K
Average Volume (3M)153.13K
Market Cap
AU$8.32M
Enterprise ValueAU$4.07
Total Cash (Recent Filing)AU$1.08M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.29
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding438,061,100
10 Day Avg. Volume271,925
30 Day Avg. Volume153,127
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.81
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Limited Debt BurdenMinimal debt reduces insolvency pressure and interest-related demands on cash. This gives Bio-Gene greater financial flexibility than a heavily leveraged business, although it does not offset the need to fund ongoing operating losses.
Losses Have Not Materially Worsened RecentlyRelative stability in losses provides a limited operating positive because deterioration has not accelerated in the latest period. However, the business remains deeply unprofitable, so this is evidence of containment rather than a demonstrated path to sustainable earnings.
Some Periods Of Improved Cash-burn PerformanceIntermittent improvement in cash burn may indicate scope for tighter cost control or reduced funding needs over the medium term. The benefit is limited because operating and free cash flow remain persistently negative and have not reached durable self-funding.
Bears Say
Revenue Has Fallen To Near-zeroNear-zero revenue leaves little evidence of commercial traction, customer adoption, or a functioning revenue engine. Unless sales recover materially, the company will struggle to absorb fixed costs, finance development, and establish a scalable operating model.
Persistent And Substantial UnprofitabilityRecurring EBIT, EBITDA, and net losses indicate that the current business model has not demonstrated sustainable economics. Continued losses can erode shareholder capital and make future growth dependent on financing rather than internally generated profits.
Ongoing Operating Cash Burn And Funding DependencePersistent operating and free-cash-flow deficits mean the business is consuming cash rather than funding itself. This raises medium-term reliance on external capital, potentially limiting strategic flexibility and exposing shareholders to dilution or funding constraints.
Bio-Gene Technology Ltd. News
BGT FAQ
What was Bio-Gene Technology Ltd.’s price range in the past 12 months?
Bio-Gene Technology Ltd. lowest share price was AU$0.02 and its highest was AU$0.06 in the past 12 months.
What is Bio-Gene Technology Ltd.’s market cap?
Bio-Gene Technology Ltd.’s market cap is AU$8.32M.
When is Bio-Gene Technology Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Bio-Gene Technology Ltd.’s earnings last quarter?
Currently, no data Available
Is Bio-Gene Technology Ltd. overvalued?
According to Wall Street analysts Bio-Gene Technology Ltd.’s price is currently Overvalued.
Does Bio-Gene Technology Ltd. pay dividends?
Bio-Gene Technology Ltd. does not currently pay dividends.
What is Bio-Gene Technology Ltd.’s EPS estimate?
Bio-Gene Technology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio-Gene Technology Ltd. have?
Bio-Gene Technology Ltd. has 438,061,100 shares outstanding.
What happened to Bio-Gene Technology Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bio-Gene Technology Ltd.?
Currently, no hedge funds are holding shares in AU:BGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bio-Gene Technology Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:BGT Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$20.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Technical Analysis
Biotron
―
Vectus Biosystems Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―